CT characteristics of non-small cell lung cancer with epidermal growth factor receptor mutation: a systematic review and meta-analysis
暂无分享,去创建一个
Zhiyong Zhang | Fei Shan | Yuesong Yang | Zenghui Cheng | Yuxin Shi | F. Shan | Yuxin Shi | Zenghui Cheng | Zhiyong Zhang | Yuesong Yang
[1] Chien-Jen Chen,et al. Epidermal Growth Factor Receptor Mutation Status in Stage I Lung Adenocarcinoma with Different Image Patterns , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[2] Jacques Ferlay,et al. Estimates of cancer incidence in China for 2000 and projections for 2005. , 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[3] Ara A Vaporciyan,et al. Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome. , 2005, Radiology.
[4] J. Goo,et al. Imaging Characteristics of Stage I Non-Small Cell Lung Cancer on CT and FDG-PET: Relationship with Epidermal Growth Factor Receptor Protein Expression Status and Survival , 2013, Korean journal of radiology.
[5] Alona Muzikansky,et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] A. Jemal,et al. Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.
[7] I. White,et al. Quantifying the impact of between-study heterogeneity in multivariate meta-analyses , 2012, Statistics in medicine.
[8] Pierre P Massion,et al. Novel strategies for the early detection and prevention of lung cancer. , 2005, Seminars in oncology.
[9] J. Doroshow. Targeting EGFR in non-small-cell lung cancer. , 2005, The New England journal of medicine.
[10] S. Fox,et al. Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond. , 2015, Translational lung cancer research.
[11] Michelle S. Ginsberg,et al. Are There Imaging Characteristics Associated with Epidermal Growth Factor Receptor and KRAS Mutations in Patients with Adenocarcinoma of the Lung with Bronchioloalveolar Features? , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[12] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[13] Kenji Suzuki,et al. Molecular markers and changes of computed tomography appearance in lung adenocarcinoma with ground-glass opacity. , 2007, Japanese journal of clinical oncology.
[14] A. Gemma,et al. F1000 highlights , 2010 .
[15] Y. Korogi,et al. Adenocarcinomas with predominant ground-glass opacity: correlation of morphology and molecular biomarkers. , 2012, Radiology.
[16] Hiroto Hatabu,et al. State of the art: Response assessment in lung cancer in the era of genomic medicine. , 2014, Radiology.
[17] T. Mok,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.
[18] N. Müller,et al. Fleischner Society: glossary of terms for thoracic imaging. , 2008, Radiology.
[19] H Nakata,et al. Evolution of peripheral lung adenocarcinomas: CT findings correlated with histology and tumor doubling time. , 2000, AJR. American journal of roentgenology.
[20] Jae Ho Lee,et al. Epidermal Growth Factor Receptor Mutation and Pathologic-Radiologic Correlation Between Multiple Lung Nodules with Ground-Glass Opacity Differentiates Multicentric Origin from Intrapulmonary Spread , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[21] G. Liu,et al. Correlation Between EGFR Mutation Status and Computed Tomography Features in Patients With Advanced Pulmonary Adenocarcinoma , 2014, Journal of thoracic imaging.
[22] Masaki Hara,et al. Epidermal Growth Factor Receptor Gene Mutation and Computed Tomographic Findings in Peripheral Pulmonary Adenocarcinoma , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[23] M. Fishbein,et al. Estrogen receptor signaling pathways in human non-small cell lung cancer , 2007, Steroids.
[24] A. Jemal,et al. Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.
[25] J. Engelman,et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.
[26] A. Jemal,et al. Global Cancer Statistics , 2011 .
[27] I. Takeyoshi,et al. Correlation between computed tomography findings and epidermal growth factor receptor and KRAS gene mutations in patients with pulmonary adenocarcinoma. , 2011, Oncology reports.
[28] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.
[29] Jeffrey W. Clark,et al. Crizotinib in ROS 1-Rearranged Non – Small-Cell Lung Cancer , 2014 .
[30] Gillian Ellison,et al. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples , 2012, Journal of Clinical Pathology.
[31] Alexander J Sutton,et al. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. , 2004, Statistics in medicine.
[32] J. Goo,et al. EGFR gene copy number in adenocarcinoma of the lung by FISH analysis: investigation of significantly related factors on CT, FDG-PET, and histopathology. , 2009, Lung cancer.
[33] F. Cappuzzo,et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.
[34] Masahiro Tsuboi,et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[35] M. Matoba,et al. Relationships between EGFR mutation status of lung cancer and preoperative factors - are they predictive? , 2014, Asian Pacific journal of cancer prevention : APJCP.
[36] Ming Liu,et al. EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity. , 2015, Lung cancer.
[37] Lu Wang,et al. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. , 2013, Cancer discovery.
[38] Sunil Singhal,et al. Prognostic Implications of Cell Cycle, Apoptosis, and Angiogenesis Biomarkers in Non–Small Cell Lung Cancer: A Review , 2005, Clinical Cancer Research.
[39] J. Minna,et al. Exclusive mutation in epidermal growth factor receptor gene, HER‐2, and KRAS, and synchronous methylation of nonsmall cell lung cancer , 2006, Cancer.
[40] William Pao,et al. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond , 2008, Modern Pathology.
[41] N. Normanno,et al. Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.
[42] A. Jemal,et al. Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.
[43] E. Felip,et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.
[44] J. Engelman,et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.
[45] S. Goodman,et al. An Epigenetic Marker Panel for Detection of Lung Cancer Using Cell-Free Serum DNA , 2011, Clinical Cancer Research.
[46] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[47] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[48] Kyung Soo Lee,et al. Ground-glass Opacity Nodules: Histopathology, Imaging Evaluation, and Clinical Implications , 2011, Journal of thoracic imaging.
[49] Lawrence H. Schwartz,et al. Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes. , 2013, Radiology.
[50] A. Gazdar. Personalized medicine and inhibition of EGFR signaling in lung cancer. , 2009, The New England journal of medicine.